Characteristics of Distress and Support Group Participation in Caregivers of Older Allogeneic Hematopoietic Cell Transplantation Patients: A Single Institution Retrospective Review.

Autor:	Elko TA; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Brown S; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Lobaugh S; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Devlin S; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Jakubowski AA; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York., Perales MA; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York., Maloy MA; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Applebaum AJ; Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York., Giralt SA; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York., Levy L; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Schneider A; Department of Social Work, Memorial Sloan Kettering Cancer Center, New York, New York., Lin RJ; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York.
Jazyk:	angličtina
Zdroj:	Journal of the advanced practitioner in oncology [J Adv Pract Oncol] 2023 Mar; Vol. 14 (2), pp. 127-137. Date of Electronic Publication: 2023 Mar 01.
DOI:	10.6004/jadpro.2023.14.2.3
Abstrakt:	Older patients with hematologic malignancies are increasingly considered for allogeneic hematopoietic cell transplant (allo-HCT). However, older patients often have increased comorbidities and thus may require an increased level of post-transplant care. These factors can contribute to increased caregiver distress, which has been associated with worsened health outcomes for caregivers and patients. To examine predictors of caregiver distress and support group participation in caregivers of older allo-HCT patients, we retrospectively reviewed charts of 208 patients aged 60 and older who underwent their first allo-HCT at our institution from 2014 through 2016. We systematically characterized and identified the incidence of caregiver distress and attendance in a caregiver support group from the start of conditioning through 1 year post allo-HCT. Evidence of caregiver distress and support group participation was recorded by reviewing clinical and/or social work documentation. We found that 20 caregivers (10%) endorsed stress and 44 caregivers (21%) attended our support group at least once. A patient's prior history of psychiatric diagnosis ( p = .046) or the use of potentially inappropriate medications for older adults ( p = .046) was found to be associated with caregiver stress. Caregivers who were spouses or partners of patients ( p = .048) or caregivers of married patients were more likely to attend the support group ( p = .007). While limited by retrospective design and likely underreporting, this study reveals factors associated with caregiver distress in the older allo-HCT caregiver population. This information can help providers identify caregivers at risk for distress and improve caregiver resources, which may improve both caregiver and patient outcomes. Competing Interests: Dr. Perales reports honoraria from Abbvie, Astellas, Bristol-Myers Squibb, Celgene, Equilium, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Novartis, Nektar Therapeutics, Omeros, Takeda, VectivBio AG, and Vor Biopharma. He serves on DSMBs for Cidara Therapeutics, Medigene, Sellas Life Sciences, and Servier, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune and Omeros. He has received research support for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, and Novartis. He serves in a volunteer capacity as a member of the Board of Directors of the American Society for Transplantation and Cellular Therapy (ASTCT) and Be The Match (National Marrow Donor Program, NMDP), as well as on the CIBMTR Cellular Immunotherapy Data Resource (CIDR) Executive Committee. Dr. Giralt serves on the scientific advisory board of Actinium, Celgene, Bristol-Myers Squibb, Sanofi, Amgen, Pfizer, GlaxoSmithKline, JAZZ, Janssen, and Omeros. He reports research consultancy for Kite. He has received research support for clinical trials from Actinium, Bristol-Myers Squibb, Celgene, Pfizer, Takeda, Janssen, Amgen, and Sanofi. Dr. Jakubowski reports ownership interest in Novartis. The other authors have no conflicts of interest to disclose. (© 2023 Harborside™.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu